Controversial advertising of medicines. A comparison between Poland and the United States

Makowska, Marta

dc.contributor.author	Makowska, Marta
dc.date.accessioned	2019-04-03T08:57:03Z
dc.date.available	2019-04-03T08:57:03Z
dc.date.issued	2018
dc.identifier.issn	1899-2226
dc.identifier.uri	http://hdl.handle.net/11089/27305
dc.description.abstract	For many years, the subject of aggressive marketing campaigns conducted by pharmaceutical companies has been raised in Poland. Drug ads are everywhere, on television, the radio, magazines and on the Internet. Therefore, it is extremely important is to ensure both their legal and ethical dimension. This article will present the differences between direct-to-consumer advertising of medicines in Poland and in the US. The dissimilarities result mainly from differences in legislation. In Poland, the law is much stricter than in the US. For example, in the United States companies are allowed to advertise prescription drugs directly to patients. In the whole of the European Union, and thus in Poland, it is strictly prohibited. The article will also present other regulations existing in Poland and in the United States and it will compare them. It will offer examples of violations of the law and ethics in the advertising of medicine in both countries. Lastly, it will briefly outline the negative consequences of unacceptable pharmaceutical marketing.	en_GB
dc.description.sponsorship	Publication of English-language versions of the volumes of the "Annales. Ethics in Economic Life" financed through contract no. 501/1/P-DUN/2017 from the funds of the Ministry of Science and Higher Education devoted to the promotion of scholarship.	en_GB
dc.language.iso	en	en_GB
dc.publisher	Wydawnictwo Uniwersytetu Łódzkiego	en_GB
dc.relation.ispartofseries	Annales. Ethics in Economic Life; 5
dc.rights	This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.	en_GB
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0	en_GB
dc.subject	pharmaceutical industry	en_GB
dc.subject	advertisement	en_GB
dc.subject	drugs	en_GB
dc.subject	law	en_GB
dc.subject	ethics	en_GB
dc.title	Controversial advertising of medicines. A comparison between Poland and the United States	en_GB
dc.type	Article	en_GB
dc.page.number	67-79
dc.contributor.authorAffiliation	Warsaw University of Life Sciences, Faculty of Social Sciences, Department of Sociology
dc.identifier.eissn	2353-4869
dc.references	Arnold, D., & Oakley, J. (2013). The politics and strategy of industry selfregulation: The pharmaceutical industry’s principles for ethical Direct-to-Consumer advertising as a deceptive blocking strategy. Journal of Health Politics, Policy and Law, 38(3), 505–544.	en_GB
dc.references	ASRC. (2012). NARB Panel Recommends Novartis Discontinue Claims that Excedrin Starts Relieving Headache Pain Faster than Advil Claims at Issue Challenged by Pfizer Consumer Healthcare. http://www.asrcreviews.org/2012/01/narb-panel-recommends-novartis-discontinue-claims-that-excedrin-starts-relieving-headache-pain-faster-than-advil-claims-at-issue-challengedby-pfizer-consumer-healthcare/	en_GB
dc.references	Blinkoff, S., & Tabela, K. (2015). USA – pharmaceutical advertising 2015. International comparative legal guides. http://www.iclg.co.uk/practice-areas/pharmaceutical-advertising/pharmaceutical-advertising-2015/usa	en_GB
dc.references	Chaniecka, K. A., & Czerw, A. (2013). Płeć a postrzeganie reklamy telewizyjnej leków OTC. Hygeia Public Health, 48, 509–514.	en_GB
dc.references	Chief Pharmaceutical Inspectorate. (2011, January 31). Decision of 31.01.2011, sign: GIF-P-R-450/106-4/JD/10/11. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/archiwum/wstrzymanie-reklam/80,Rok-2011.html	en_GB
dc.references	Chief Pharmaceutical Inspectorate. (2012, April 26). Decision of 26.04.2012, sign: GIF-P-R-450/14-2/JD/12,2012. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/archiwum/wstrzymanie-reklam/79,Rok-2012.html	en_GB
dc.references	Chief Pharmaceutical Inspectorate. (2014, September 9). Decision of 11.09.2014, sign: GIF-P-R-450/46-2/JD/14. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/decyzje/619,Decyzja-z-dnia-11092014-znak-GIF-P-R-45046-2JD14.html.	en_GB
dc.references	Chief Pharmaceutical Inspectorate. (n.d.) Decisions and messages. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/decyzje	en_GB
dc.references	Committee of Advertising Ethics [Rada Reklamy]. (2011). Uchwała Nr ZO 40/11 w sprawie reklamy firmy Novartis Poland Sp. z o.o. [Resolution No. ZO40/11 regarding the advertising of Novartis Poland Sp. z o.o.].https://www.radareklamy.pl/uchwaly-ker/2011/uchwa%C5%82a-nr-zo-40-11 -w-sprawie-reklamy-firmy-novartis-poland-sp-z-o-o	en_GB
dc.references	Committee of Advertising Ethics [Rada Reklamy]. (2014). Uchwała Nr ZO 64/14 w sprawie reklamy firmy Pfizer Trading Polska Sp. z o.o. [Resolution No.ZO 64/14 regarding the advertising of Pfizer Trading Polska Sp. z o.o.].https://www.radareklamy.pl/uchwaly-ker/2014/uchwa%C5%82a-nr-zo-64-14-w-sprawie-reklamy-firmy-pfizer-trading-polska-sp-z-o-o	en_GB
dc.references	Committee of Advertising Ethics [Rada Reklamy]. Commission of Ethics [Komisja Etyki Reklamy]. https://www.radareklamy.pl/komisja-etyki-reklamy	en_GB
dc.references	Consumer Healthcare Products Association. (2015). OTC Drug Advertising. http://www.chpa.org/OTCDrugAdvertising.aspx	en_GB
dc.references	Diehl, S., Mueller, B., & Terlutter, R. (2008). Consumer responses towards nonprescription and prescription drug advertising in the US and Germany: They don’t really like it, but they do believe it. International Journal of Advertising, 27(1), 99–131.	en_GB
dc.references	Donohue, J. (2006). A history of drug advertising: The evolving roles of consumers and consumer protection. Milbank Quarterly, 84, 659–699.	en_GB
dc.references	Faerber, A. E., & Kreling, D. H. (2012). Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs. Journal of General Internal Medicine, 29(1), 110–118.	en_GB
dc.references	Food and Drugs Administration. (2014a). Cipher Pharmaceuticals Inc. Warning Letter. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ UCM415228.pdf	en_GB
dc.references	Food and Drugs Administration. (2014b). Pacira Pharmaceuticals, Inc. Warning Letter. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM416514.pdf	en_GB
dc.references	Food and Drugs Administration. (2015a). Drug Applications for Over-the-Counter (OTC) Drugs. https://www.fda.gov/drugs/developmentapprovaprocess/howdrugsaredevelopedandapproved/approvalapplications/over-the-counterdrugs/default.htm	en_GB
dc.references	Food and Drugs Administration. (2015b). Inspections, Compliance, Enforcement, and Criminal Investigations, Warrning Letters, Drugs. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/default.htm	en_GB
dc.references	Food and Drugs Administration. (n.d.). Prescription Drug Advertising. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/default.htm	en_GB
dc.references	Frosch, D., Kruger, P. M., Hornik, R. C., Cronholm, P., & Barg, F. (2007). Creating demand for prescription drugs: A content analysis of television Directto-Consumer advertising. Annals of Family Medicine, 1(5), 6–13.	en_GB
dc.references	Journal of Laws of the Republic of Poland 1991, No. 105, position 452. Act on pharmaceuticals, medical materials, pharmacies, wholesalers and pharmaceutical supervision. [Dz.U. 1991, No. 105, item 452, Ustawao środkach farmaceutycznych, materiałach medycznych, aptekach, hurtowniach i nadzorze farmaceutycznym].	en_GB
dc.references	Journal of Laws of the Republic of Poland 1993, No. 47, position 211. The Act on Combating Unfair Competition. [Dz.U. 1993, No. 47, item 211, Ustawa ozwalczaniu nieuczciwej konkurencji].	en_GB
dc.references	Journal of Laws of the Republic of Poland 2008, No. 45, position 271. Pharmaceutical Law. [Dz.U. 2008, No. 45, item 271, Prawo Farmaceutyczne].	en_GB
dc.references	Koncerny farmaceutyczne mocno inwestują w reklamę. Aflofarm na czele peletonu. (2014). www.marketingprzykawie.pl. http://www.marketingnews.pl/ theme.php?art=1804.	en_GB
dc.references	KPMG & IAA. (2015). Rynek reklamy telewizyjnej w Polsce po latach wychodzi na prostą. Warsaw.	en_GB
dc.references	Kravitz, R. L. (2000). Direct-to-Consumer advertising of prescription drugs. Western Journal of Medicine, 173(4), 221–222.	en_GB
dc.references	Kula, P. (2015). Pharmaexpert podsumowuje rynek apteczny w 2014 roku. http://www.aptekarzpolski.pl/2015/02/01-2015-pharmaexpert-podsumowuje-rynek-apteczny-w-roku-2014/	en_GB
dc.references	Mack, J. (2015). Increased DTC advertising and rising drug prices – Is there a causal link? http://pharmamkting.blogspot.com/2015/11/increased-dtc-advertising-and-rising.html	en_GB
dc.references	Makowska, M. (2010). Etyczne standardy marketingu farmaceutycznego. Warszawa: CeDeWu.	en_GB
dc.references	Makowska, M. (2016). Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce. Warszawa: Wydawnictwo Szkoły Głównej Gospodarstwa Wiejskiego.	en_GB
dc.references	Michalski, B., Sławatyniec, Ł., Duczyńska, M., & Kęska, K. (2013). Prawo farmaceutyczne i refundacja leków. Warszawa: Wolters Kluwer.	en_GB
dc.references	Mogull, S. A. (2008). Chronology of Direct-to-Customer advertising regulation in the United States. American Medical Writers Association Journal, 23(3), 106–109.	en_GB
dc.references	PAIiIZ. (2013). Sektor faramaceutyczny i biotechnologiczny w Polsce. Warszawa: The Polish Investment and Trade Agency.	en_GB
dc.references	Stange, K. C. (2007). Time to ban Direct-to-Consumer prescription drug marketing. Annals of Family Medicine, 5(2), 101–104.	en_GB
dc.references	Sudak, I. (2015, March 4). My, Polacy, lekomani. Rekordowe wydatki na leki, groźne skutki reklam. Gazeta Wyborcza. http://wyborcza.biz/biznes/1,100896,17513743,My__Polacy__lekomani__Rekordowe_wydatki_na_leki__grozne.html#ixzz3uwzWsiDa	en_GB
dc.references	Szuba, T. (1994). Polityka leku w Polsce. Aptekarz, 2(9), 379–386.	en_GB
dc.references	Szuba, T. (2003). Ekonomka leku. Podręcznik dla studentów farmacji i farmaceutów. Aptekarz, 11(10), 257–292.	en_GB
dc.references	Ventola, C. (2011). Direct-to-Consumer pharmaceutical advertising. Therapeutic or toxic? Pharmacy and Therapeutics, 10(36), 669–684.	en_GB
dc.references	Zarzeczna-Baran, M., Bandurska, E., Pęgiel-Kamrat, J., & Lewandowska, A. (2013). The impact of advertising on purchase of OTC drugs. Annales Academiae Medicae Gedanensis, 43, 77–87.	en_GB
dc.contributor.authorEmail	marta_makowska@sggw.pl
dc.identifier.doi	10.18778/1899-2226.21.5.06
dc.relation.volume	21	en_GB
dc.subject.jel	I18
dc.subject.jel	M31
dc.subject.jel	M38

Pliki tej pozycji

Nazwa:: 5_6_67-79_Makowska M..pdf
Rozmiar:: 524.4KB
Format:: PDF

Oglądaj/Otwórz

Pozycja umieszczona jest w następujących kolekcjach

Annales. Etyka w życiu gospodarczym 2018, vol. 21 nr 5 [12]

Pokaż uproszczony rekord

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Poza zaznaczonymi wyjątkami, licencja tej pozycji opisana jest jako This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.